NIV-NAVA vs NIV-PS/PC in Respiratory Insufficiency

Overview

This study evaluates the difference between Non Invasive Ventilation with Neurally Adjusted Ventilatory Assist (NIV-NAVA) and Conventional Non Invasive Ventilation with Pressure Support (PS) or Pressure Control (PC). All the patients are ventilated in each mode for 4 hours. Afterwards they will be subjected to a semi-structured interview where they will be asked to compare the two modes. The hypothesis is that NIV-NAVA will correct patients power of Hydrogen (pH), PaCO2 og PaO2 more quickly than NIV-PS and NIV-NAVA is more comfortable for the patients.

Full Title of Study: “Non-Invasive Ventilation With Neurally Adjusted Ventilatory Assist vs NIV Pressure Support or Pressure Control in Treatment of Patients With Acute Respiratory Insufficiency. A Prospective, Randomised, Single Blinded, Crossover Pilot Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: April 2017

Detailed Description

Neurally Adjusted Ventilatory Assist (NAVA) is a ventilation mode where the diaphragm is controlling the amount of ventilatory assistance proportionally through a nasogastric tube containing electrodes which are sending the electrical activities of the diaphragm (Eadi) to the ventilator. Whereas Conventional ventilation modes like Pressure support or Pressure Control are dependent on the pressure drop or flow reversal to initiate assist delivered to the patient. This is last step of the signal chain leading to inhalation and is subject to disturbances such as intrinsic positive expiratory end pressure (PEEP), hyperinflation and leakage.

Interventions

  • Other: NIV-NAVA
    • Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
  • Other: NIV-PS/PC
    • Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.

Arms, Groups and Cohorts

  • NIV-NAVA
    • 4 hour NIV-NAVA, followed by 4 hour NIV-PS/PC
  • NIV-PS/PC
    • 4 hour NIV-PS/PC, followed by 4 hour NIV-NAVA

Clinical Trial Outcome Measures

Primary Measures

  • Time for normalizing of Power of Hydrogen (pH) in arterial blood gases. Normal pH frame 7.35-7.45.
    • Time Frame: 8 hours
  • Time for normalizing of Partial pressure of Oxygen (pO2) in arterial blood gases. Normal frame for pO2 7-14,4 (or to the usual level for the patient).
    • Time Frame: 8 hours
  • Time for normalizing Carbon dioxide partial pressure (pCO2) in arterial blood gases. Normal frames pCO2 4,7-6,4 (or to the usual level for the patient).
    • Time Frame: 8 hours
  • Electrical activity of the diaphragm (Eadi). Reduction in respiratory work assessed by Eadi (in percentage).
    • Time Frame: 8 hours

Secondary Measures

  • Patient comfort
    • Time Frame: 24 hours
    • There will be conducted a semi-interview on the subjects. They will be asked: If they felt any difference in breathing between the two modes. If yes, what was the difference? Which method did you prefer? And why? Do you have any comments?

Participating in This Clinical Trial

Inclusion Criteria

  • Patients admitted at the ICU with acute respiratory insufficiency and therefore have hypoxia(PaO2 < 7 kPa on atmospheric air) og pH < 7.35 with non-compensated hypercapnia (PaCO2 > 6.0 kPa). – Patients, which according to the departments guidelines are required to treatment with NIV Exclusion Criteria:

  • Patients under years of 18. – Patients without the possibility to give informed consent. – Patients with neuromuscular or neurological disease. – Patients with a verified or suspected head trauma. – Patients with a acknowledged hiatus hernia. – Patients with an active or suspected active upper GI bleeding. – Patients which have previously been in the study. – Patients with a suspected or verified acute coronary syndrome.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Vejle Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Alan Kimper-Karl, MD, Study Chair, Vejle Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.